Mood and Anxiety Disorders Rounds
This site made possible through independent sponsorships from Lundbeck Canada, AstraZeneca Canada, Pfizer Canada Inc and Bristol-Myers Squibb Canada




Total: 12



Review of Novel Antipsychotics Used in Mood Disorders: An In-class Examination
By Carl Chiniara, MD, and Serge Beaulieu, MD, PhD, FRCPC
Antipsychotics are widely used in the treatment of various psychiatric conditions such as schizophrenia and other psychotic disorders, major depressive disorder, bipolar I and II disorders, severe dementia with psychosis or inappropriate behaviours, irritability in autistic disorders, acute agitation, delirium, treatment-resistant obsessive-compulsive disorder,
treatment-resistant posttraumatic stress disorder, tic disorders, trichotillomania, and other off-label uses.



Assessment and Treatment of Cognitive Deficits in Adults with Mood Disorders: Restoring Function
By Vina M. Goghari, PhD, RPsych, and Glenda M. MacQueen, MD, PhD, FRCPC
Major depressive disorder (MDD) and bipolar disorder (BD) are among the 10 most debilitating mental or physical illnesses in terms of number of healthy years lost to illness. These disorders have a major economic impact through both health costs and loss of work productivity.



Anxiety Disorders in the DSM-5:
New Rules on Diagnosis and Treatment

By Cara Katz, BSc, Murray B. Stein, MD, FRCPC, and Jitender Sareen, MD, FRCPC
Anxiety disorders are among the most common mental disorders, with a lifetime prevalence of 16%–29%. In addition to provoking substantial disability, anxiety disorders are highly comorbid with other mental and physical disorders, thus complicating the treatment of both types of disorders.



CANMAT 2013 Update of Guidelines for the
Management of Patients with Bipolar Disorder

By Sagar V. Parikh, MD, FRCPC, and Benjamin Goldstein, MD, PhD, FRCPC
Bipolar disorder (BD) is among the most challenging conditions for clinicians to treat, a challenge that CANMAT has attempted to address through publication of treatment guidelines for BD in 1997, 2005, 2007, 2009, and now with a 2013 update.



The Canadian Biomarker Integration Network for Depression (CAN-BIND): Looking Deeper into Major Depressive Disorder
By Susan Rotzinger, PhD, and Sidney Kennedy, MD, FRCPC,
on behalf of the CAN-BIND Team
The increasing prevalence of depressive disorders and the limited efficacy and escalating costs associated with current treatments led a group of physicians at the University of Toronto to create CAN-BIND.



Clinically Significant Drug Interactions in Mood Disorders: Maximizing Benefit, Minimizing Risk
By Marie-Josée Filteau, MD, FRCPC, and Jacinthe Leblanc, BPharm, DPH
Most patients suffering from unipolar and bipolar mood disorders and anxiety disorders require multimodal treatments, including pharmacotherapy, psychotherapy, and long-term lifestyle changes. The therapeutic objective of any major unipolar depression treatment is the functional recovery of an asymptomatic patient.



Post-traumatic Stress Disorder: Guiding
Management with Careful Assessment
of Comorbid Mental and Physical Illness

By J. Don Richardson, MD, FRCPC, Diane McIntosh, MD, FRCPC, Murray B. Stein, MD, FRCPC, and Jitender Sareen, MD, FRCPC
Post-traumatic stress disorder (PTSD) is a common and serious psychiatric condition in the civilian and veteran population. The lifetime prevalence of PTSD in the Canadian general population is 9.2%, which, surprisingly, is not significantly different from the 7.2% lifetime prevalence rate within the Canadian Regular Forces.



Gambling Problems and Mood Disorders:
Increasing the Odds of Successful Management

By Brenda Welsh, HBHSc, BScN, and Sidney H. Kennedy, MD, FRCPC
Gambling is defined as offering up money or a substance of value in a game of chance for a return that is uncertain. According to Statistics Canada, 73% of Canadians reported having gambled in at least one form in 2006.



Guidelines for the Safety Monitoring of Patients With Bipolar Disorder
Valerie Taylor, MD, PhD, FRCPC, and Ayal Schaffer, MD, FRCPC
All patients undergoing treatment for bipolar disorder (BD) require some form of medical safety monitoring. The type and frequency of monitoring depends not only on the specific medication prescribed, but also on the specific patient profile and treatment setting.



A Neurobiological Rationale for Exercise in the Treatment of Bipolar Disorder
By Mohammad T. Alsuwaidan, MD, and Roger S. McIntyre, MD, FRCPC
Exercise is known to have beneficial psychological, immunomodulatory, metabolic, and cellular effects. This issue of Mood and Anxiety Disorders Rounds discusses the rationale for physical exercise as a treatment for bipolar disorder (BD) and part of a multimodal chronic disease management approach.



CANMAT Clinical Guidelines for the Management of Major Depressive Disorder in Adults: A Summary of
Pharmacotherapy Recommendations

George Hadjipavlou, MD, FRCPC, and Raymond W. Lam, MD, FRCPC
In 2009, the Canadian Network for Mood and Anxiety Treatments (CANMAT) published a major update of the 2001 evidence-based clinical guidelines for the management of depressive disorders in adults that were originally produced in collaboration with the
Canadian Psychiatric Association. This issue of Mood and Anxiety Disorders Rounds summarizes the pharmacotherapy section3 of these guidelines that address major depressive disorder (MDD).



CANMAT and the ISBD Collaborative 2009
Update of Guidelines for the Management
of Patients with Bipolar Disorder: A Review

By David J. Bond, MD, FRCPC and Lakshmi N. Yatham, MBBS, FRCPC
Combined, bipolar disorder I (BDI) and bipolar disorder II (BDII) affect 2.1% of the population, or over 700,000 Canadians. When softer forms of BD, referred to as bipolar disorder not otherwise specified (BDNOS) or “bipolar spectrum disorders,” are included, the lifetime prevalence may be as high as 4.5%. Excellence in the management of BD is thus a core competency for all psychiatrists.

Total: 12